Only three stocks were in the top 10 for both the strategy and the benchmark: Merck MRK, JPMorgan Chase ... have joined this team since 2017. Betsy George arrived in 2017 from another Wellington ...

Only three stocks were in the top 10 for both the strategy and the benchmark: Merck MRK, JPMorgan Chase ... have joined this team since 2017. Betsy George arrived in 2017 from another Wellington ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Fintel reports that on February 18, 2025, Deutsche Bank downgraded their outlook for Merck (SNSE:MRKCL) from Buy to Hold. There are 5,199 funds or institutions reporting positions in Merck.

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Fintel reports that on February 18, 2025, Deutsche Bank downgraded their outlook for Merck (XTRA:6MK) from Buy to Hold. As of January 29, 2025, the average one-year price target for Merck is 120 ...

Robert F. Kennedy Jr. is not qualified to be health and human services secretary for many reasons, chief among them being his years-long unscientific campaign against essential vaccines.

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...